Welcome to our dedicated page for KESTRA MEDICAL TECHNOLOGIES, LTD. SEC filings (Ticker: KMTS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on KESTRA MEDICAL TECHNOLOGIES, LTD.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into KESTRA MEDICAL TECHNOLOGIES, LTD.'s regulatory disclosures and financial reporting.
T. Rowe Price Associates, Inc. reports beneficial ownership of 4,968,900 shares of Kestra Medical Technologies common stock, representing 8.5% of the class as of June 30, 2026. The firm has sole voting power over 4,966,936 shares and sole dispositive power over 4,968,900 shares, with no shared voting or dispositive power. T. Rowe Price Associates states that this report should not be construed as an admission that it is the beneficial owner of these securities, and such beneficial ownership is expressly denied.
Kestra Medical Technologies CFO Vaseem Mahboob reported selling a total of 26,287 Common Shares of KMTS on August 7, 2026 in two open-market transactions under a Rule 10b5-1 trading plan adopted November 6, 2025. The reported sales occurred at weighted average prices of $25.8742 and $26.3300 per share, with detailed price ranges disclosed in the footnotes.
Kestra Medical Technologies, Ltd. filed a notice of proposed sale of restricted securities. The filing covers a planned sale of 26,287 shares of common stock through Merrill Lynch, with an aggregate market value of $680,383.99, when the issuer had approximately 58,602,497 shares of common stock outstanding. The securities relate to performance share unit awards that vested on July 14, 2026 and were granted under the issuer’s equity compensation plan.
The reporting security holder, Vaseem Mahboob, also lists prior sales of common stock during the past three months: 3,980 shares on July 30, 2026 for $90,560.62; 8,817 shares on July 31, 2026 for $199,344.62; 5,391 shares on August 3, 2026 for $128,312.27; and 6,995 shares on August 4, 2026 for $172,634.70.
Kestra Medical Technologies Chief Commercial Officer Alfred J. Ford Jr. reported a nondiscretionary sale of 6,275 common shares on 2026-08-04 to satisfy tax withholding obligations arising from the vesting and settlement of restricted stock units. The shares were sold at a weighted average price of $24.0862, with prices ranging from $23.9000 to $24.5700. Following this tax-related sale, he directly holds 99,564 common shares of Kestra Medical Technologies.
Kestra Medical Technologies Chief Financial Officer Mahboob Vaseem reported selling 6,995 common shares on August 4, 2026. A sale of 3,080 shares at a weighted average $24.057 was a nondiscretionary sell-to-cover for RSU tax withholding, and a separate 3,915-share sale at $25.1696 occurred under a Rule 10b5-1 trading plan adopted November 6, 2025.
KESTRA MEDICAL TECHNOLOGIES, LTD. executive Traci S. Umberger, General Counsel and Chief Administrative Officer, reported a non-discretionary sale of 3,580 common shares on August 4, 2026, to cover tax withholding obligations arising from the vesting and settlement of restricted stock units. The sale was executed at a weighted average price of $24.0428 per share, with individual prices ranging from $23.8000 to $24.4200.
Following this tax-related sale, Umberger directly holds 195,825 common shares of Kestra Medical Technologies, Ltd.
Kestra Medical Technologies, Ltd.'s President and Chief Executive Officer, Brian Daniel Webster, reported selling 51,900 common shares of KMTS on August 4, 2026, across three sale transactions. Footnotes state these were nondiscretionary sell-to-cover sales to satisfy tax withholding obligations from restricted stock unit vesting, including 48,625 shares at a weighted average price of $24.4692 per share.
Kestra Medical Technologies, Ltd. reports a planned sale of up to 51,900 common shares through Merrill Lynch on NASDAQ, with an aggregate value of $1,272,585.45. The shares relate to a 07/17/2026 performance stock issuance granted under an equity compensation plan and follow multiple prior common share sales over recent months.
Kestra Medical Technologies, Ltd. (KMTS) has a proposed sale of 3,580 shares of common stock through Merrill Lynch on 08/04/2026, following the 07/17/2026 vesting of restricted stock unit awards granted as equity compensation. The Form 144 also lists prior sales over the last three months by reporting person Traci Umberger.
Kestra Medical Technologies, Ltd. insider Alfred J. Ford filed notice of a planned sale of 6,275 shares of common stock through Merrill Lynch on NASDAQ on 08/04/2026, with an indicated value of $151,140.78. These shares relate to restricted stock units that vest on 07/17/2026 under the issuer’s equity compensation plan.
Over the prior three months, Alfred J. Ford reported sales of 5,936 shares for $135,120.73 on 07/30/2026, 8,681 shares for $196,284.58 on 07/31/2026, and 13,015 shares for $311,118.83 on 08/03/2026.